Access the full text.
Sign up today, get DeepDyve free for 14 days.
U. Bertsche, A. Mader, U. Zimmermann (1988)
Nuclear membrane fusion in electrofused mammalian cells.Biochimica et biophysica acta, 939 3
M. Lo, T. Tsong, M. Conrad, S. Strittmatter, L. Hester, S. Snyder (1984)
Monoclonal antibody production by receptor-mediated electrically induced cell fusionNature, 310
S. Foung, S. Perkins, K. Kafadar, P. Gessner, U. Zimmermann (1990)
Development of microfusion techniques to generate human hybridomas.Journal of immunological methods, 134 1
K. Ohnishi, J. Chiba, Y. Goto, T. Tokunaga (1987)
Improvement in the basic technology of electrofusion for generation of antibody-producing hybridomas.Journal of immunological methods, 100 1-2
J. Schmitt, U. Zimmermann (1989)
Enhanced hybridoma production by electrofusion in strongly hypo-osmolar solutions.Biochimica et biophysica acta, 983 1
U. Zimmermann, J. Schmitt, P. Kleinhans (1988)
The Potential of Electrofusion for Hybridoma Production
R. Däumler, U. Zimmermann (1989)
High yields of stable transformants by hypo-osmolar plasmid electroinjection.Journal of immunological methods, 122 2
K. James, G. Bell (1987)
Human monoclonal antibody production. Current status and future prospects.Journal of immunological methods, 100 1-2
U. Zimmermann, P. Gessner, R. Schnettler, S. Perkins, S. Foung (1990)
Efficient hybridization of mouse-human cell lines by means of hypo-osmolar electrofusion.Journal of immunological methods, 134 1
S. Foung, S. Perkins (1989)
Electric field-induced cell fusion and human monoclonal antibodies.Journal of immunological methods, 116 1
Andrew Saxon, Joanne Feldhaus, R.Adrian Robins (1976)
Single step separation of human T and B cells using AET treated srbc rosettes.Journal of immunological methods, 12 3-4
Hypoosmolar conditions have permitted the development of electrofusion techniques capable of producing human hybridomas from as few as 10 5 B cells. A hybridoma formation efficiency of one hybrid for each 125 input B cells has been achieved with Epstein-Barr virus-activated B cells and mouse–human heteromyelomas. This is at least 100-fold higher in efficiency than with polyethylene glycol-induced cell fusion, as well as a 50- to 100-fold decrease in the required number of human B cells. The ability to fuse a small number of input B cells should lead to a greater success rate in immortalizing the rare antigen-specific B cells. The critical parameters include fusion voltages, the composition and number of wash steps used in cell preparation, the composition and duration of exposure to hypoosmolar fusion medium, fusion ratio, plating density, the use of growth medium without pH indicator, and the use of an irradiated human fibroblast feeder layer. By manipulating these parameters, a high hybrid yield can be achieved with different mouse–human heteromyelomas and Epstein-Barr virus–activated B cells.
Human Antibodies – IOS Press
Published: Jan 1, 1991
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.